Adjustment to Net Income (Loss): Mark to Market Available-for-sale Securities
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
An analysis of the financial results from 2020 to 2024 reveals significant volatility in both reported and adjusted net income, characterized by periodic fluctuations and varying degrees of divergence between the two metrics.
- Net Income Volatility
- Reported net income exhibited a fluctuating pattern, peaking in 2023 at 8,344 million US dollars before declining to 4,614 million US dollars by 2024. A notable contraction occurred in 2022, where income fell to 4,149 million US dollars, representing a substantial decrease from the 7,910 million US dollars recorded in 2021.
- Variance Between Reported and Adjusted Net Income
- The relationship between reported and adjusted net income shifted inconsistently over the five-year period. In 2020 and 2023, adjusted net income exceeded reported figures, suggesting the impact of non-recurring charges or losses. Conversely, in 2021 and 2022, reported net income was higher than adjusted net income, indicating the presence of non-operating gains or adjustments that inflated the reported bottom line relative to adjusted operational performance.
- Analysis of Significant Divergences
- The most pronounced discrepancy occurred in 2022, where reported net income of 4,149 million US dollars was significantly higher than the adjusted net income of 1,870 million US dollars, a variance of 2,279 million US dollars. This trend reversed sharply in 2023, with adjusted net income exceeding reported net income by 1,090 million US dollars.
- Convergence in 2024
- By the end of 2024, a convergence between the two metrics is observed. Reported net income of 4,614 million US dollars and adjusted net income of 4,644 million US dollars show a minimal variance of 30 million US dollars, suggesting a stabilization in the adjustments applied to the net income figures.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Profitability Ratios: Mark to Market Available-for-sale Securities (Summary)
CVS Health Corp., Profitability Ratios: Reported vs. Adjusted
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
The profitability metrics exhibit a cyclical pattern of contraction and recovery between 2020 and 2024, characterized by significant downturns in 2022 and 2024.
- Net Profit Margin Analysis
- Reported net profit margins fluctuated between a high of 2.72% in 2021 and a low of 1.24% in 2024. The adjusted net profit margin exhibited greater volatility, plummeting to 0.58% in 2022 before rebounding to 2.65% in 2023 and declining again to 1.25% in 2024. This volatility suggests that adjusted earnings were more sensitive to non-recurring items than reported figures during the 2022 period.
- Return on Equity (ROE) Trends
- Return on Equity demonstrates substantial variance over the five-year period. Reported ROE peaked at 10.91% in 2023 but experienced notable contractions to 5.84% in 2022 and 6.11% in 2024. The adjusted ROE highlights a more extreme volatility, falling to a low of 2.63% in 2022 before surging to 12.34% in 2023, indicating that adjusted results were heavily influenced by specific accounting adjustments or one-time financial events.
- Return on Assets (ROA) Performance
- ROA patterns align closely with the trends observed in ROE and profit margins. Reported ROA remained relatively stable between 3.11% and 3.39% from 2020 to 2021, before dropping to 1.82% in 2022, recovering to 3.34% in 2023, and returning to 1.82% in 2024. The adjusted ROA showed a more severe contraction in 2022, reaching 0.82%, which suggests a temporary reduction in asset-generating efficiency on an adjusted basis.
A consistent divergence between reported and adjusted figures is observed throughout the period, most notably in 2022, where adjusted ratios were significantly lower than reported ratios. The repeated pattern of decline in 2022 and 2024 across all three primary profitability indicators suggests recurring headwinds impacting overall financial efficiency.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Net Profit Margin
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 Net profit margin = 100 × Net income attributable to CVS Health ÷ Revenues from customers
= 100 × 4,614 ÷ 370,656 = 1.24%
2 Adjusted net profit margin = 100 × Adjusted net income attributable to CVS Health ÷ Revenues from customers
= 100 × 4,644 ÷ 370,656 = 1.25%
The financial performance from 2020 to 2024 is characterized by significant volatility in profitability margins and net income. The adjusted net profit margin demonstrates a cyclical pattern of contraction and recovery, indicating substantial fluctuations in operational efficiency or the impact of non-recurring items.
- Adjusted Net Profit Margin Trends
- A period of relative stability is observed between 2020 and 2021, with the adjusted net profit margin moving from 2.84% to 2.57%. A severe contraction occurred in 2022, where the margin fell to a period low of 0.58%. This was followed by a sharp recovery in 2023, returning to 2.65%, before declining again to 1.25% in 2024.
- Net Income Volatility
- Adjusted net income mirrored the margin trends, showing a drastic decline from US$ 7,474 million in 2021 to US$ 1,870 million in 2022. A peak was reached in 2023 with adjusted net income ascending to US$ 9,434 million, the highest value in the observed period, followed by a reduction to US$ 4,644 million in 2024.
- Comparative Analysis of Reported and Adjusted Metrics
- Significant divergence between reported and adjusted figures is evident, particularly in 2022, where the reported net profit margin (1.29%) was more than double the adjusted margin (0.58%). In contrast, for the year 2023, the adjusted net income of US$ 9,434 million exceeded the reported net income of US$ 8,344 million, suggesting that the adjustments neutralized specific costs or losses. By 2024, the reported and adjusted net profit margins converged, ending at 1.24% and 1.25% respectively.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Return on Equity (ROE)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROE = 100 × Net income attributable to CVS Health ÷ Total CVS Health shareholders’ equity
= 100 × 4,614 ÷ 75,560 = 6.11%
2 Adjusted ROE = 100 × Adjusted net income attributable to CVS Health ÷ Total CVS Health shareholders’ equity
= 100 × 4,644 ÷ 75,560 = 6.15%
The financial performance from 2020 through 2024 is characterized by significant volatility in both profitability and shareholder returns. A cyclical pattern of contraction and recovery is evident, with a notable trough occurring in 2022 and a sharp peak in 2023, followed by a substantial decline in 2024.
- Net Income Trends
- Reported net income fluctuated from a high of 8,344 million USD in 2023 to a low of 4,149 million USD in 2022. Adjusted net income exhibited even greater variance, plummeting to 1,870 million USD in 2022 before surging to a period peak of 9,434 million USD in 2023. By the end of 2024, adjusted net income contracted sharply to 4,644 million USD, representing a reduction of approximately 50.8% from the previous year's peak.
- Adjusted Return on Equity (ROE) Analysis
- The adjusted ROE demonstrates extreme instability over the five-year period. After remaining relatively stable around 10% in 2020 and 2021, the ratio collapsed to 2.63% in 2022. A strong recovery occurred in 2023, with the adjusted ROE reaching its maximum value of 12.34%. However, this momentum was not sustained, as the ratio fell to 6.15% by December 31, 2024, indicating a diminished efficiency in generating profits from shareholders' equity.
- Comparative Variance Between Reported and Adjusted Metrics
- There is a marked divergence between reported and adjusted ROE during periods of financial stress and recovery. In 2022, the reported ROE of 5.84% was significantly higher than the adjusted ROE of 2.63%, suggesting that non-recurring items inflated the reported figure. Conversely, in 2023, the adjusted ROE of 12.34% exceeded the reported ROE of 10.91%, indicating that adjustments removed negative non-recurring impacts to reveal a stronger underlying operational performance. By 2024, the two metrics converged closely at 6.11% and 6.15%, respectively.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?
Adjusted Return on Assets (ROA)
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
2024 Calculations
1 ROA = 100 × Net income attributable to CVS Health ÷ Total assets
= 100 × 4,614 ÷ 253,215 = 1.82%
2 Adjusted ROA = 100 × Adjusted net income attributable to CVS Health ÷ Total assets
= 100 × 4,644 ÷ 253,215 = 1.83%
The financial performance between 2020 and 2024 is characterized by significant volatility in profitability and asset utilization efficiency. A pattern of sharp fluctuations is evident, particularly from 2022 onward, where both reported and adjusted metrics experienced substantial declines, followed by a temporary recovery in 2023 and a subsequent drop in 2024.
- Adjusted Return on Assets (ROA) Trend
- The Adjusted ROA remained relatively stable between 2020 and 2021, moving from 3.30% to 3.21%. A severe contraction occurred in 2022, with the ratio falling to 0.82%, marking the lowest efficiency level in the analyzed period. This was followed by a sharp rebound to a five-year peak of 3.78% in 2023, before declining again to 1.83% by the end of 2024.
- Net Income Volatility
- Adjusted net income exhibits higher variance than reported net income. In 2022, adjusted net income fell to 1,870 million USD, which was significantly lower than the reported 4,149 million USD. Conversely, in 2023, adjusted net income rose to 9,434 million USD, exceeding the reported figure of 8,344 million USD. By 2024, the figures converged, with reported net income at 4,614 million USD and adjusted net income at 4,644 million USD.
- Comparative Analysis of Reported and Adjusted ROA
- Reported ROA generally tracks the trajectory of Adjusted ROA but exhibits less extreme swings. The most notable divergence occurred in 2022, when Reported ROA stood at 1.82% while Adjusted ROA dropped to 0.82%. By 2024, the two metrics aligned almost identically at 1.82% for Reported ROA and 1.83% for Adjusted ROA, suggesting that the impact of adjustments on asset efficiency became negligible by the end of the period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
How can I help you?